Nautilus Biotechnology is trading 10.38% higher at $2.87, with no clear company-specific announcement identified to explain the October 23, 2026 move.
- Q3 results are scheduled for October 27; they are upcoming, not a reported catalyst for the rise.
- Major indices are lower, so market context does not explain the stock’s move in the same direction.
- No reliable current volume figure is available.